Pier Capital LLC Acquires New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Pier Capital LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 272,372 shares of the company’s stock, valued at approximately $1,588,000.

Other institutional investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at $30,000. Teacher Retirement System of Texas acquired a new stake in Olema Pharmaceuticals in the fourth quarter valued at $60,000. Vontobel Holding Ltd. acquired a new stake in Olema Pharmaceuticals in the fourth quarter valued at $62,000. Fox Run Management L.L.C. bought a new position in Olema Pharmaceuticals during the 4th quarter worth $80,000. Finally, SG Americas Securities LLC lifted its holdings in Olema Pharmaceuticals by 33.8% during the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after buying an additional 4,419 shares during the period. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OLMA has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.

Olema Pharmaceuticals Stock Up 2.1 %

OLMA stock opened at $4.32 on Tuesday. The firm has a market cap of $247.53 million, a price-to-earnings ratio of -1.97 and a beta of 2.11. The company’s fifty day simple moving average is $5.08 and its 200 day simple moving average is $8.25. Olema Pharmaceuticals, Inc. has a 12-month low of $3.94 and a 12-month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. Research analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was purchased at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the purchase, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.